Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

被引：83

作者：

Minnema, MC

Breitkreutz, I

Auwerda, JJA

van der Holt, B

Cremer, FW

van Marion, AMW

Westveer, PHM

Sonneveld, P

Goldschmidt, H

Lokhorst, HM

机构：

[1] Univ Med Ctr, Dept Haematol, NL-3584 CX Utrecht, Netherlands

[2] Heidelberg Med Univ, Heidelberg, Germany

[3] Erasmus Med Ctr Rotterdam, Rotterdam, Netherlands

[4] Hovon Data Ctr, Rotterdam, Netherlands

来源：

LEUKEMIA | 2004年 / 18卷 / 12期

关键词：

D O I：

10.1038/sj.leu.2403533

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2044 / 2046

页数：4

共 7 条

[1] Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].

Barlogie, B ;

Jagannath, S ;

Desikan, KR ;

Mattox, S ;

Vesole, D ;

Siegel, D ;

Tricot, G ;

Munshi, N ;

Fassas, A ;

Singhal, S ;

Mehta, J ;

Anaissie, E ;

Dhodapkar, D ;

Naucke, S ;

Cromer, J ;

Sawyer, J ;

Epstein, J ;

Spoon, D ;

Ayers, D ;

Cheson, B ;

Crowley, J .

BLOOD, 1999, 93 (01) :55-65

[2] Thalidomide in multiple myeloma: Current status and future prospects [J].

Cavenagh, JD ;

Oakervee, H .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :18-26

[3] Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy [J].

Cavo, M ;

Zamagni, E ;

Cellini, C ;

Tosi, P ;

Cangini, D ;

Cini, M ;

Valdrè, L ;

Palareti, G ;

Masini, L ;

Tura, S ;

Baccarani, M .

BLOOD, 2002, 100 (06) :2272-2273

[4] Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment [J].

Minnema, MC ;

Fijnheer, R ;

De Groot, PG ;

Lokhorst, HM .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (03) :445-449

[5] Deep venous thrombosis and thalidomide therapy for multiple myeloma. [J].

Osman, K ;

Comenzo, R ;

Rajkumar, SV .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1951-1952

[6] Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy [J].

Zangari, M ;

Anaissie, E ;

Barlogie, B ;

Badros, A ;

Desikan, R ;

Gopal, AV ;

Morris, C ;

Toor, A ;

Siegel, E ;

Fink, L ;

Tricot, G .

BLOOD, 2001, 98 (05) :1614-1615

[7] Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study [J].

Zervas, K ;

Dimopoulos, MA ;

Hatzicharissi, E ;

Anagnostopoulos, A ;

Papaioannou, A ;

Mitsouli, C ;

Panagiotidis, P ;

Korantzis, J ;

Tzilianos, M ;

Maniatis, A .

ANNALS OF ONCOLOGY, 2004, 15 (01) :134-138

← 1 →